Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
Several other research firms also recently issued reports on APTO. ValuEngine raised shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, April 3rd. Roth Capital set a $6.00 price target on shares of Aptose Biosciences and gave the stock a “buy” rating in a research note on Monday, April 16th. Finally, HC Wainwright set a $6.00 price target on shares of Aptose Biosciences and gave the stock a “buy” rating in a research note on Monday, April 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $5.63.
Aptose Biosciences opened at $3.34 on Wednesday, according to Marketbeat.com. The firm has a market cap of $102.22 million, a price-to-earnings ratio of -6.42 and a beta of 2.38. Aptose Biosciences has a 52-week low of $3.30 and a 52-week high of $3.36.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings data on Tuesday, March 27th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01). equities research analysts predict that Aptose Biosciences will post -0.72 EPS for the current year.
An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC lifted its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 316.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,421 shares of the biotechnology company’s stock after buying an additional 33,766 shares during the period. Acadian Asset Management LLC owned approximately 0.17% of Aptose Biosciences worth $100,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.05% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Get a free copy of the Zacks research report on Aptose Biosciences (APTO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.